Literature DB >> 30203054

Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.

Paul A Newhouse1,2.   

Abstract

Year:  2019        PMID： 30203054      PMCID： PMC6379030          DOI： 10.1093/ntr/nty189

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN： 1462-2203            Impact factor:   4.244


× No keyword cloud information.
  52 in total

1.  Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease.

Authors:  A Potter; J Corwin; J Lang; M Piasecki; R Lenox; P A Newhouse
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

2.  Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.

Authors:  G Dunbar; P H Boeijinga; A Demazières; C Cisterni; R Kuchibhatla; K Wesnes; R Luthringer
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 3.  Nicotinic Acetylcholine Receptor Ligands, Cognitive Function, and Preclinical Approaches to Drug Discovery.

Authors:  Alvin V Terry; Patrick M Callahan
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

4.  Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans.

Authors:  Caterina Gratton; Sahar Yousef; Esther Aarts; Deanna L Wallace; Mark D'Esposito; Michael A Silver
Journal:  J Neurosci       Date:  2017-03-23       Impact factor: 6.167

5.  EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.

Authors:  Jos Prickaerts; Nick P van Goethem; Richard Chesworth; Gideon Shapiro; Frank G Boess; Christoph Methfessel; Olga A H Reneerkens; Dorothy G Flood; Dana Hilt; Maria Gawryl; Sonia Bertrand; Daniel Bertrand; Gerhard König
Journal:  Neuropharmacology       Date:  2011-11-10       Impact factor: 5.250

6.  Cholinergic Receptor Binding in Alzheimer Disease and Healthy Aging: Assessment In Vivo with Positron Emission Tomography Imaging.

Authors:  David L Sultzer; Rebecca J Melrose; Hannah Riskin-Jones; Theresa A Narvaez; Joseph Veliz; Timothy K Ando; Kevin O Juarez; Dylan G Harwood; Arthur L Brody; Mark A Mandelkern
Journal:  Am J Geriatr Psychiatry       Date:  2017-01-04       Impact factor: 4.105

Review 7.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Authors:  Edward D Levin; F Joseph McClernon; Amir H Rezvani
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 8.  Beyond Acetylcholinesterase Inhibitors: Novel Cholinergic Treatments for Alzheimer's Disease.

Authors:  Asante R Kamkwalala; Paul A Newhouse
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

Review 9.  Human neuronal nicotinic receptors.

Authors:  C Gotti; D Fornasari; F Clementi
Journal:  Prog Neurobiol       Date:  1997-10       Impact factor: 11.685

10.  Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.

Authors:  Richard S E Keefe; Herbert A Meltzer; Nancy Dgetluck; Maria Gawryl; Gerhard Koenig; Hans J Moebius; Ilise Lombardo; Dana C Hilt
Journal:  Neuropsychopharmacology       Date:  2015-06-19       Impact factor: 7.853
View more
  2 in total

1.  Bio-oils from vacuum ablative pyrolysis of torrefied tobacco residues.

Authors:  Nattawut Khuenkaeo; Blake MacQueen; Thossaporn Onsree; Sangu Daiya; Nakorn Tippayawong; Jochen Lauterbach
Journal:  RSC Adv       Date:  2020-09-22       Impact factor: 3.361

Review 2.  The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders.

Authors:  Sofia Eickhoff; Leon Franzen; Alexandra Korda; Helena Rogg; Valerie-Noelle Trulley; Stefan Borgwardt; Mihai Avram
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.